Lexaria Bioscience Corp Stock Price, News & Analysis

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced a new broadcast titled, "The Power of Science to Stop a Killer," focusing on its patented drug-delivery technology, DehydraTECH(TM). This innovation enhances the absorption of active pharmaceutical ingredients (APIs), potentially addressing the global anti-hypertensive market, valued at $24.17 billion in 2020 and projected to reach $27.81 billion by 2025. Hypertension contributes to significant healthcare costs, estimated at $131 billion annually in the U.S., with over 670,000 related deaths in 2020.

Lexaria Bioscience Corp. (NASDAQ: LEXX) announces its feature in a NetworkNewsWire editorial, highlighting advancements in hypertension treatment. With nearly 114 million American adults affected by hypertension, the company leverages its patented DehydraTECH(TM) technology to enhance drug delivery, potentially revolutionizing hypertension therapeutics. Lexaria's technology improves bioabsorption of active ingredients, reducing onset time significantly. The firm holds 25 patents and has 50 more pending, promoting its innovative approach in the pharmaceutical landscape.

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful completion of dosing in its clinical hypertension study, HYPER-H21-4, involving 64 patients. The study was randomized, double-blind, and placebo-controlled, aimed at assessing the safety and efficacy of DehydraTECH-CBD. Notably, no serious adverse events were reported, marking a significant safety milestone. The findings are anticipated to support an IND application to the FDA for further clinical testing. Secondary outcomes will include various cardiovascular health metrics, brain function, and overall health assessments, with data analyses expected to begin in September.

Lexaria Bioscience Corp. has issued a five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals for the European, Australian, and New Zealand markets. The license allows AnodGen to manufacture and distribute cannabinoid active pharmaceutical ingredient powders and mandates royalty payments to Lexaria for all sales. This partnership aims to enhance bioavailability and absorption of cannabinoid products. AnodGen plans to operationalize its facility in Ireland by the end of 2022, aiming for significant growth in the pharmaceutical sector.

Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has filed a pre-Investigational New Drug (IND) meeting request with the FDA, successfully initiating communication regarding its DehydraTECH-CBD for hypertension treatment. The FDA confirmed receipt and set a target date of July 30, 2022 for follow-up, contingent on meeting specific conditions. This meeting aims to clarify Lexaria's IND-enabling development program ahead of a full IND application expected later in 2022 or early 2023. The hypertension market, valued at $28 billion, presents significant potential for Lexaria's innovative drug delivery technology.

Lexaria Bioscience Corp. (LEXXW, LEXX) has entered into a significant licensing agreement with Premier Wellness Science Co., Ltd. to utilize its DehydraTECH technology in the Japanese non-pharmaceutical market. Premier will make minimum payments of US$4,527,500 over five years to retain exclusivity, along with receiving royalty revenue from product sales. This partnership aims to address the booming Japanese CBD market, projected to exceed US$35 billion annually. Premier's parent company reported US$187 million in revenue for the first three quarters of 2021, signaling robust market potential.

Lexaria Bioscience Corp. announced the licensing of its DehydraTECH technology to Valcon Medical A/S, a European contract manufacturing organization. This license targets medical cannabis applications in the EU and UK. Lexaria is set to receive milestone fees and royalties from product sales, optimizing revenue potential as Valcon manufactures various cannabis products. Valcon's GMP certification enhances their credibility in the market. This collaboration aims to capitalize on the growing demand for effective medical cannabis solutions.

Lexaria Bioscience Corp. held its 2022 Annual Meeting on May 31, with 49.2% of shares represented. Key voting results included:

• Chris Bunka elected with 97.15% approval
• John Docherty elected with 87.25% approval
• Nicholas Baxter elected with 84.5% approval
• Ted McKechnie elected with 96.1% approval
• Albert Reese Jr. elected with 96.56% approval
• Davidson & Company LLP appointed as auditors with 98.77% approval
• Non-binding compensation approval for executives at 93.52%
• Directors' past actions ratified at 91.1%

Lexaria Bioscience Corp. (NASDAQ: LEXX) has announced the availability of a new broadcast titled, “Nicotine Surges as Smoking Sags.” The global smoking cessation market is projected to grow significantly, with nicotine pouch sales expected to rise from $2.33 billion in 2020 to $21.84 billion by 2027. Lexaria's DehydraTECH technology enhances drug absorption, evidenced by its ability to boost cannabinoid and nicotine bioabsorption significantly. With 25 patents granted and 50 pending, Lexaria aims to expand applications of its technology for various pharmaceuticals.